Axa
AXDX

Axa’s Accelerate Diagnostics AXDX Stock Holding History

Axa’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-91,351
Closed -$1.32M – 1115
2022
Q1 		$1.32M Sell
91,351
-43,251
-32% -$1.23M ﹤0.01% 909
2021
Q4 		$7.03M Sell
134,602
-24,233
-15% -$1.35M 0.02% 578
2021
Q3 		$9.26M Sell
158,835
-4,716
-3% -$308K 0.03% 518
2021
Q2 		$13.2M Buy
163,551
+914
+0.6% +$72.7K 0.04% 458
2021
Q1 		$13.5M Sell
162,637
-3,269
-2% -$332K 0.04% 446
2020
Q4 		$12.6M Sell
165,906
-14,174
-8% -$1.27M 0.04% 442
2020
Q3 		$19.2M Sell
180,080
-23,961
-12% -$3.33M 0.07% 294
2020
Q2 		$30.9M Buy
204,041
+4,225
+2% +$417K 0.12% 199
2020
Q1 		$16.6M Sell
199,816
-4,468
-2% -$629K 0.08% 250
2019
Q4 		$34.5M Buy
204,284
+25,041
+14% +$4.13M 0.14% 183
2019
Q3 		$33.3M Buy
179,243
+2,992
+2% +$578K 0.13% 204
2019
Q2 		$40.3M Buy
176,251
+132,624
+304% +$25.9M 0.16% 181
2019
Q1 		$9.17M Sell
43,627
-3,860
-8% -$724K 0.04% 475
2018
Q4 		$5.46M Buy
47,487
+7,117
+18% +$1.05M 0.02% 579
2018
Q3 		$9.27M Buy
40,370
+2,322
+6% +$513K 0.03% 500
2018
Q2 		$8.48M Buy
38,048
+6,796
+22% +$1.52M 0.03% 502
2018
Q1 		$7.14M Buy
31,252
+150
+0.5% +$39.4K 0.03% 550
2017
Q4 		$8.15M Sell
31,102
-12,163
-28% -$2.85M 0.03% 532
2017
Q3 		$9.71M Buy
43,265
+12,404
+40% +$3.05M 0.04% 444
2017
Q2 		$8.44M Buy
+30,861
New +$8.36M 0.04% 463

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Axa's AXDX Position: Q2 2022 in Review

Axa sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 91,351 shares — an estimated $1.32M sold.

Axa first reported a position in AXDX in Q2 2017 and held it in 20 quarters. The position peaked at $40.3M in Q2 2019. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • Axa reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Axa sold 91,351 Accelerate Diagnostics shares in Q2 2022, an estimated $1.32M.
  • Axa first reported a position in Accelerate Diagnostics in Q2 2017 and held it in 20 quarters.
  • Axa's Accelerate Diagnostics position peaked at $40.3M in Q2 2019.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Axa's 13F filing for Q2 2022, filed 15 Aug 2022.